CERP, SWVI & Extended Watchlist

Cereplast, Inc. CERP

After appearing on yesterday’s extended watchlist, CERP gapped up slightly at the open .0288 from the prior close of .0248. We saw a slight pullback to fill part of that gap, with the stock dipping as low as .025 first thing yesterday morning, after which it proceeded to push to a high of .0449 by early afternoon. The differential from low to high produced an opportunity for us to rake in up to 80% in profits on the day.

This stock is coming off of a dead-cat bottom, so we’d like to see it get above the 50DMA of .0552 for us to remain bullish. As you can see on the chart, indicators are starting to look strong, with the RSI coming off of being oversold and getting ready to pass through the 50-line. The PPO and the Slow STO just crossed over, and momentum is looking strong, with volume picking up over the past few days.


Swingplane Ventures Inc. SWVI

SWVI is another stock off of our extended watchlist from yesterday- this one gapped up to .19 after a previous close at .17. We saw a slight pullback to .1843, before the stock surged as high as .295 (closed @ .2899). In all, total intraday gains of 60% were possible, on huge volume to the tune of 88M shares.

We want to be cautious here, even while there may be gains still left to be made. We’ve seen a few large promo outfits touting this stock recently, so we just need to keep aware, and scan for the impending collapse that most often follows a big promotional push. The tail-end of those pullbacks generally produce bounceplay opportunities, of which we fully intend to take advantage. It will be all about timing when this comes to pass. We’ve been spot-on in timing the actions of SWVI so far, so join us in keeping this play on your watchlist as this round of promotions runs its course.


Side Note:

Of the remaining three stocks to appear on yesterday’s extended watchlist, two posted gains on the day: Pharma-plays PATH and KERX. It was actually the third day running that we mentioned PATH, which has made gains of 21% over just a few short days; quite a feat for a big board stock. This was on the strength of a news release outlining the company’s new treatment for acute migraines.


Extended Watchlist: